Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



ELI LILLY AND COMPANY Stock Hits Price Target Forecast with 25.96% Profit

May 16, 2023
ELI LILLY AND COMPANY's stock recently achieved the price target forecast set by QuantWave, resulting in a profit of 25.96%. The forecast signal was issued on February 14, 2023, when the stock was priced at 341.75 $. The predicted direction was long, and on May 16, 2023, the stock reached the target price of 430.47 $.

This success can be attributed to several market factors, including positive earnings reports, favorable industry trends, and strong investor confidence in the company's pipeline of pharmaceutical products. ELI LILLY AND COMPANY's stock movement also reflects broader market shifts and economic conditions.

QuantWave's accurate forecast for ELI LILLY AND COMPANY demonstrates the platform's effectiveness in providing valuable insights for investors. With QuantWave, users can access predictions for a wide range of stocks, presenting opportunities for potential profits. For a more in-depth understanding of QuantWave's investment strategy, investors are encouraged to explore QuantSchool's educational resources, which offer a professional framework for utilizing the forecasting system.

Overall, the achievement of the price target forecast for ELI LILLY AND COMPANY's stock highlights the power of QuantWave's analytics in guiding successful investment decisions.
If you want to leave a comment, then you need Login or Register





Other data for LLY

Related data

LLYJuly 20, 2025Strong Q2 Forecast for ELI LILLY AND COMPANY by J.P. Morgan  ~1 min.

According to J.P. Morgan, Eli Lilly and Company is expected to have a strong second quarter performance. The pharmaceutical giant has been receiving positive attention from investors and analysts alike....

LLYMarch 22, 2025Eli Lilly and Company LLY: Leading the Way in Pharmaceutical Innovation  ~2 min.

Eli Lilly and Company (LLY) continues to make waves in the pharmaceutical industry with its innovative and groundbreaking therapies....

LLYMarch 19, 2025Eli Lilly and Company LLY Surges After Breakthrough BRAVE-AA-PEDS Study Results  ~2 min.

Eli Lilly and Company (LLY) has recently made a significant breakthrough in its BRAVE-AA-PEDS study, resulting in a surge of investor attention and market gains....

LLYMarch 18, 2025Eli Lilly and Company: A Promising Investment in the Pharma Industry  ~1 min.

Eli Lilly and Company (LLY) has been making waves in the pharmaceutical industry with its innovative products and strong performance....

LLYMarch 17, 2025Eli Lilly and Company's Groundbreaking Discovery Revolutionizes Pharma Industry  ~2 min.

Eli Lilly and Company, a renowned pharmaceutical giant, has recently made a groundbreaking discovery that is set to revolutionize the entire industry....

LLYMarch 16, 2025Is Eli Lilly and Company LLY Set to Revolutionize the Pharma Industry?  ~2 min.

Eli Lilly and Company (LLY) has been making headlines recently with its groundbreaking research and innovative products....

LLYMarch 14, 2025Eli Lilly and Company Reports Promising Results in Hair Regrowth Study  ~1 min.

Eli Lilly and Company (LLY) recently announced the positive outcome of their Phase 3 clinical trial for baricitinib, a drug aimed at treating severe alopecia areata in adolescents....

LLYFebruary 28, 2025Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding 50 billion  ~1 min.

Eli Lilly and Company (LLY) is set to significantly increase its manufacturing investment in the United States, surpassing a staggering 50 billion since 2020....

LLYFebruary 27, 2025Eli Lilly and Company Acquires Organovos FXR Program in IBD Treatment Development  ~1 min.

Eli Lilly and Company has recently made headlines with its acquisition of Organovos FXR Program, a significant step towards advancing treatment options for Inflammatory Bowel Disease (IBD)....

LLYFebruary 26, 2025ELI LILLY AND COMPANY Launches Additional Zepbound Vial Doses and Offers New Savings  ~2 min.

ELI LILLY AND COMPANY has recently announced the launch of additional Zepbound vial doses, as well as new savings for self-pay patients....

REGNApril 4, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 16.89% Profit  ~1 min.

QuantWave's forecast for REGENERON PHARMACEUTICALS, INC. proved accurate as the stock reached the predicted target price on April 4, 2025....

REGNApril 4, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave Forecast Target with Profit of 15.56%  ~1 min.

REGENERON PHARMACEUTICALS, INC. has successfully reached the price target forecast set by QuantWave on April 4, 2025....

VRTXJune 4, 2024VERTEX PHARMACEUTICALS Stock Hits Forecasted Price Target with 14.32% Profit: QuantWave Analysis  ~1 min.

VERTEX PHARMACEUTICALS INCORPORATED has successfully reached the price target forecasted by QuantWave, resulting in a profitable outcome for investors....

VRTXAugust 9, 2022Vertex Pharmaceuticals Incorporated Hits Price Target Forecast with 9.92% Profit  ~1 min.

Vertex Pharmaceuticals Incorporated (VRTX) has successfully achieved the price target forecast set by QuantWave, resulting in a profit of 9.92%....

VRTXJuly 9, 2025VERTEX PHARMACEUTICALS INCORPORATED Hits QuantWave Forecast Target with 7.59% Profit  ~2 min.

VERTEX PHARMACEUTICALS INCORPORATED (VRTX) has successfully reached the forecast price target set by QuantWave on June 30, 2025....